US Patent 7829064 Anti-CD74 immunoconjugates and methods
Patent 7829064 was granted and assigned to IMMUNOMEDICS, INC. on November, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+401 characters)
Article
Patent abstract
Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates compositions in therapeutic and/or diagnostic methods.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Bo B. Lundberg0
David M. Goldenberg0
Gary L. Griffiths0
Hans J. Hansen0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07829064 Anti-CD74 immunoconjugates and methods US Patent 7829064 Anti-CD74 immunoconjugates and methods
Infobox
Patent Number
078290640
Patent Number
78290640
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078290640
Date of Patent
November 9, 2010
0Patent Application Number
107068520
Date Filed
November 12, 2003
0Official Website
Patent Primary Examiner
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07829064 Anti-CD74 immunoconjugates and methods
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07829064
Date of patent
November 9, 2010
Patent application number
10706852
Date Filed
November 12, 2003
Patent primary examiner
Find more entities like US Patent 7829064 Anti-CD74 immunoconjugates and methods
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
